← All trials
NCT06014190
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2023
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2027
- First posted
- Aug 28, 2023
- Last posted
- Aug 28, 2023
- Enrollment
- 460
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Lead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Fujian Medical UniversityOverall official - principal investigator
- Hainan People's HospitalOverall official - principal investigator
- Henan Medical UniversityOverall official - principal investigator
- Wuhan UniversityOverall official - principal investigator
- Central South UniversityOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- Hebei UniversityOverall official - principal investigator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Central South UniversityOverall official - principal investigator
- Xinjiang Medical UniversityOverall official - principal investigator
- Cancer Hospital of Yunnan provincealOverall official - principal investigator
- Chinese Academy of Medical SciencesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.